Abstract
Aims Gastric cancer (GC) represents a global health-care challenge. In recent years, a large number of competing endogenous RNA (ceRNA) network studies have elucidated critical long non-coding RNAs (lncRNAs) as potential prognostic biomarkers in GC. Nevertheless, there is no systematic review and meta-analysis regarding them. Here, we propose a systematic review and meta-analysis for lncRNAs as prognostic biomarkers based on the ceRNA network studies in GC.
Main methods The Web of Science, Embase, PubMed, Scopus, ProQuest and Google Scholar databases were searched to collect eligible ceRNA network studies in which lncRNAs were reported as prognostic biomarkers until 27th June 2022. The pooled hazard ratios (HRs) were assessed to evaluate the prognostic effect of the lncRNAs. Prognostic values of highly reported lncRNAs were also examined. Furthermore, sensitivity analysis, and publication bias were evaluated.
Key findings Totally, 35 studies were included in the systematic review among which 13 studies were eligible for meta-analysis. Pooled examination of HRs based on the univariate and multivariate reports revealed that the expression changes of the lncRNAs correlate with overall survival (OS) of GC patients. Two lncRNAs including CCDC144NL-AS1 and LINC01094 were highly reported as potential prognostic biomarkers based on the ceRNA network studies. Prognostic value of these two lncRNAs was furthermore confirmed by meta-analysis.
Significance Our meta-analysis demonstrated potential application of lncRNAs introduced based on the ceRNA network studies as promising prognostic biomarkers in GC. Further functional studies are needed to elucidate the molecular mechanisms underlying these lncRNAs’ functions in GC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Isfahan University of Medical Sciences in Isfahan, Iran, provided funding for this study [grant number 140166].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is a systematic review and meta-analysis which conducted meta-analysis on published papers reporting ceRNA networks mainly based on the data of TCGA (https://portal.gdc.cancer.gov/) and GEO (https://www.ncbi.nlm.nih.gov/geo/) databases. The study protocol was approved by the Ethics Committee of Isfahan University of Medical Sciences and is available from here: https://ethics.research.ac.ir/ProposalCertificateEn.php?id=262634&Print=true&NoPrintHeader=true&NoPrintFooter=true&NoPrintPageBorder=true&LetterPrint=true.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This study is a systematic review and meta-analysis which conducted meta-analysis on published papers reporting ceRNA networks mainly based on the data of TCGA (https://portal.gdc.cancer.gov/) and GEO (https://www.ncbi.nlm.nih.gov/geo/) databases.
